A number of well-known pharmaceutical companies have been sold to further increase the concentration of the pharmaceutical industry?

With the continuous advancement of pharmaceutical policies, the structural adjustment of pharmaceutical companies has never stopped

01 sale or acquisition

In the second half of the year, the sale of assets or shares by pharmaceutical companies continued to occur.

Kyrgyzstan Pharmaceutical Holdings

On September 27, Jilin Pharmaceutical Holdings issued a reminder announcement on planning for the sale of major assets and signing the "Share Transfer Framework Agreement", announcing that it would sell 99.

Jiangzhong Pharmaceutical

On September 17, Jiangzhong Pharmaceutical issued an announcement that it intends to acquire 51% of Jincheng Haisi Pharmaceutical Co.

Minimally Invasive Medicine

On September 13, MicroPort Medical issued an announcement stating that its subsidiary Shanghai MicroPort Medical Equipment (Group) Co.

As a strategic investor, Shanghai MicroPort will acquire 45% of Fujian Kerui Pharmaceutical Co.

Conbay

On September 29, Kang Enbei officially announced the listing and transfer of its two major subsidiaries.

Conba has been making frequent moves in asset restructuring since September

On September 13, Kang Enbei announced that it had agreed to the company’s wholly-owned subsidiary Hangzhou Kang Enbei Pharmaceutical Co.

Nanjing Hi-Tech

On September 8, Nanjing Hi-Tech stated that the company's listed and transferred holding subsidiary Nanjing Chengong Pharmaceutical Co.

Boya Biopharmaceuticals

On September 1, Boya Bio-Pharmaceutical Group Co.

Judging from the announcements issued by many companies, there are different reasons for these actions

For example, Jiangzhong Pharmaceutical said that after the completion of the transaction, it can enrich its product structure with the help of Hayes Pharmaceuticals products, improve the business layout of Jiangzhong Pharmaceuticals in the gastrointestinal field, and thereby enhance the company's profitability

If acquisitions can enrich the industrial layout of pharmaceutical companies, then the effect of selling assets should not be underestimated

Take Kang En Bay as an example.

The sale of Guizhou Beite is because the sales of Danshen Ligustrazine injection produced by Guizhou Beite have continued to drop significantly.

Industry insiders believe that under the promotion of the normalization of policies such as volume procurement, whether it is chemical drugs, traditional Chinese medicines or insulin, etc.
Avoid
.

02 Transformation and development

Like all industries, the pharmaceutical industry is also facing a certain elimination rate
.
After the announcement of the fifth batch of national procurement results, Hengrui Medicine stated in its semi-annual report that it would promote operational reforms and accelerate transformation and upgrading
.

At the 2021 Xipu meeting just held in September, Bian Jianping, a partner of Nordson Creative Alliance, said that according to Nordson Creative Alliance's survey, more than half of the doctors believe that online visits are the future trend
.

The virtual representation model will combine big data to analyze doctors’ profile and channel preferences, reach out to doctors in a multi-channel way, and promote brand concept communication and effect enhancement
.

In other words, part of the work of medical representatives will be replaced by machines in the future
.
Not only pharmaceutical companies, but the transformation of pharmaceutical representatives is also imminent
.

According to the "Statistical Analysis Report on the Operation of the Pharmaceutical Circulation Industry in 2020" issued by the Ministry of Commerce, as the reform of the medical and health system continues to deepen, the pharmaceutical circulation industry is accelerating the pace of transformation and upgrading.
Steady and positive momentum
.

It can be seen that the development trend of the pharmaceutical circulation industry is that the mergers and acquisitions and reorganization of the industry have become more stable, and strong cooperation has become the mainstream
.

With the intensification of the reshuffle of the pharmaceutical industry, the innovation and development of pharmaceutical companies has become the main direction
.

In the "Fourteenth Five-Year Plan for Medical Security for All" issued by the General Office of the State Council just a few days ago, it was mentioned that we should continue to encourage drug innovation and development, accelerate the launch of new drugs and good drugs, and promote the development and use of new drugs and medical devices that are urgently needed by the masses.

.

Among them, steadily advancing the quality and efficacy consistency evaluation of generic drugs, strict drug supervision, and orderly advancing the construction of a drug traceability system are the keys
.

This is often the case in the pharmaceutical industry.
In the reshuffle of mergers and reorganizations, pharmaceutical companies that are unwilling to make consistency evaluations will undoubtedly be eliminated
.

In the future, as the integration and mergers of the pharmaceutical industry continue, the industrial structure of pharmaceutical companies may change.
Only companies with strong alliances and more innovative can better occupy the market
.